Navigation Links
Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
Date:4/23/2013

ek 4 and <25 IU/mL undetectable at week 12. In patients meeting RGT criteria, HCV therapy was stopped at week 24. All other patients continued treatment until week 48.

About Simeprevir

Simeprevir (TMC435) is an investigational NS3/4A protease inhibitor jointly developed by Janssen and Medivir AB for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis. Simeprevir is believed to work by blocking the protease enzyme that enables the hepatitis C virus to survive and replicate in host cells. Janssen recently announced the submission of new drug applications for simeprevir in Japan and the United States for the treatment of genotype 1 hepatitis C, and anticipates submitting simeprevir for regulatory authorization in the EU in the first half of 2013.

Global Phase 3 studies of simeprevir include QUEST-1 and QUEST-2 in treatment-naive adult patients, PROMISE in patients who have relapsed after prior interferon-based treatment and ATTAIN in null-responder adult patients. In parallel to these trials, Phase 3 studies for simeprevir are ongoing in treatment-naive and treatment-experienced HIV-HCV co-infected patients and HCV genotype 4 patients. To date, 1,846 patients have been treated with simeprevir in clinical trials.

Simeprevir is also being studied in Phase 2 interferon-free trials with and without ribavirin in combination with:

  • Janssen's non-nucleoside inhibitor TMC647055 and ritonavir in treatment-naive genotype 1a and 1b HCV patients;
  • Gilead Sciences, Inc.'s nucleotide inhibitor sofosbuvir (GS-7977) in treatment-naive and previous null-responder genotype 1 HCV patients; and
  • Bristol- Myers Squibb 's NS5A replication complex inhibitor daclatasvir (BMS-790052) in treatment-naive and previous null-resp
    '/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Managed Health Care Associates, Inc. (MHA) Released Results of Sixth Annual Independent Long Term Care Member Study with Expanded Specialty Pharmacy Findings
2. Dr. Kevin Foley to Present DiscGenics Recent Findings at the Lumbar Spine Research Societys Annual Meeting
3. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
4. HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
5. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
6. New Findings Offer Systemic Solutions to Address Non-communicable Diseases (NCDs) in Low- and Middle-income Countries
7. Proof of Concept Study Initial Findings
8. French Lifestyle Secret Finally Revealed: Lycotec Publishes Unexpected Findings on Roquefort Cheese
9. ENDECE Neural to Present Findings for Remyelination at 2013 Keystone Symposia on Multiple Sclerosis
10. New Findings Link Telehealth-Enabled Care Coordination with Reduced Mortality for Patients with Congestive Heart Failure
11. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... --  MultiVir Inc. ("MultiVir"), a clinical-stage gene therapy ... the treatment of multiple oncological indications, today announced that ... S-1 with the U.S. Securities and Exchange Commission ("SEC") ... of its common stock. The number of shares to ... offering have not yet been determined. MultiVir has applied ...
(Date:3/30/2015)... -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE ) announced ... to the position of Executive Vice President & Chief ... responsible for all legal, compliance and intellectual property functions. ... Sciences International, Inc., where he was Senior Vice President ... that led that company to over a six fold ...
(Date:3/30/2015)... Alere Inc. (NYSE: ALR ), a ... today in support of President Barack Obama,s ... "As the global leader in rapid diagnostics for ... for establishing a National Action Plan with measurable goals ... antibiotic resistance. We look forward to continuing to work ...
Breaking Medicine Technology:MultiVir Files Registration Statement for Proposed Initial Public Offering 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 3Alere Applauds President's National Action Plan to Combat Antibiotic-Resistant Bacteria 2
(Date:3/30/2015)... March 30, 2015 Wright & Schulte ... lawsuits, notes that the number of Syngenta corn ... underway in U.S. District Court, District of Kansas, have ... 2014. "According to an update released by the U.S. ... at least 493 Syngenta lawsuits are now consolidated in ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 A new ... in California Superior Court on behalf of a child ... defect after his mother was prescribed the anti-nausea medication ... March 6th filing in Alameda Superior Court, the baby’s ... vomiting that she experienced in the early months of ...
(Date:3/30/2015)... Los Angeles, CA (PRWEB) March 30, 2015 ... “6 New Ways to Blast Away Fat,” details six new ... these treatments require injections and one is a topical product. ... ( UltraShape and Liposonix ) or freezing cold ... “There are so many options now available to us to ...
(Date:3/30/2015)... 2015 In a recent report published ... Chris Christie is championing effective drug and alcohol treatment ... scrambling to recover funds to stabilize the addiction treatment ... victims of drug and alcohol addiction. Harbor Village Detox ... by substance use disorders in New Jersey, in hopes ...
(Date:3/30/2015)... 2015 This report studies the ... the forecast period of 2014 to 2019. This ... of 6.5% from 2014 to 2019. , Further ... report, the global pharmacovigilance and drug safety software ... the basis of functionality, namely, adverse event reporting ...
Breaking Medicine News(10 mins):Health News:Syngenta Corn Lawsuit Claims Continue To Be Filed By Non GMO Corn Farmers Reports Wright & Schulte LLC 2Health News:Syngenta Corn Lawsuit Claims Continue To Be Filed By Non GMO Corn Farmers Reports Wright & Schulte LLC 3Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 2Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 3Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 4Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4
... Brain Institute (QBI) have now found a process that ... from dementia and acquired brain injury. ,The research ... associated with memory function and where the brain's ability ... with age. ,The study by Dr Natalie Bull ...
... conducted by researchers at University of Texas Southwestern Medical ... problem //faced by diabetics by increasing their blood pressure. ... professor and chief of the division of nutrition and ... a high-carb diet on blood pressure with a diet ...
... Germany’s drugs firm Grunenthal has developed a new drinking ... bitter medicine// to their children. The straw contains and ... neutral taste. The straw also contains a filter which ... been taken. ,The tasteless cover of the granulated ...
... Harming Themselves To Get Relief From Frustrations. ,UK based ... the country inflict injuries upon themselves due to feelings ... upon themselves has been contemplated by 20% of the ... have actually harmed themselves. ,The Priory survey ...
... implicated as a causative factor in many different forms of ... cancer and respiratory diseases // . For example, 1/3rd of ... are being taken by members of the scientific community to ... and to help curb the same. ,A new ...
... claim that the weight gained during the holiday season is ... ,The weight gain starts from the Thanksgiving weekend ... battle of the holiday bulge., ,To stop this bulge ... have more fruits and non-fat yogurt, drink skimmed milk, drink ...
Cached Medicine News:Health News:Research Targets treatment for dementia and brain injuries 2Health News:Carbohydrate-rich Diet In Diabetes Raises Blood Pressure 2Health News:Most Smokers Continue To Smoke Despite Developing Cancer 2
Protologics Corporation announces ProtoCLAIMS, Web-based electronic claims product that links and reconciles desktop claims with insurance payers who offer direct claims processing....
... and Collections Administrator has a maximum ... models and personalized paper or electronic ... ability to facilitate rebilling, ledger notes, ... from the Onscreen Collections Worksheet and ...
Visionary OFFICE™ PM offers a Windows interface featuring medical billing, appointment scheduling and patient information....
A.I.med's medical billing software is a medical billing software. The billing module integrates with A.I.med's Electronic Medical Record software. A.I.med's medical billing module also integrates wit...
Medicine Products: